A Comparison of Attitudes Toward Pharmacological Treatment Versus Enhancement Under Competitive and Noncompetitive Conditions

REFERENCES

• Academy of Medical Sciences. 2007. Drugsfutures: Public engagement on the future of brain science, addiction and drugs. London, UK : Office of Project Management.
   Google Scholar
• Arria, A.M., K.M. Caldeira, K.B. Vincent, K.E. O’Grady, and E.D. Wish. 2008. Perceived harmfulness predicts nonmedical use of prescription drugs among college students: interactions with sensation-seeking. Prevention Science 9(3): 191–201.
   PubMed Web of Science ®Google Scholar
• Banjo, O.C., R. Nadler, and P.B. Reiner. 2010. Physician attitudes towards pharmacological cognitive enhancement: Safety concerns are paramount. PLoS One 5(12): e14322.
   PubMed Web of Science ®Google Scholar
• Bell, S., B. Partridge, J. Lucke, and W. Hall. 2013. Australian university students’ attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics 6: 197–205.
   Web of Science ®Google Scholar
• Bergström, L.S., and N. Lynöe. 2008. Enhancing concentration, mood and memory in healthy individuals: An empirical study of attitudes among general practitioners and the general population. Scandinavian Journal of Public Health 36(5): 532–537.
   PubMed Web of Science ®Google Scholar
• Bolt, I., and M. Schermer. 2009. Psychopharmaceutical enhancers: Enhancing identity? Neuroethics 2(2): 103–111.
   Web of Science ®Google Scholar
• Bostrom, N., and A. Sandberg. 2009 Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics 15(3): 311–341.
   PubMed Web of Science ®Google Scholar
• Brantigan, C.O., T.A. Brantigan, and N. Joseph. 1982. The effect of beta blockade and beta stimulation on stage fright. American Journal of Medicine 72(1): 88–94.
   PubMed Web of Science ®Google Scholar
• Caplan, A.L. 2003. Is better best? A noted ethicist argues in favor of brain enhancement. Scientific American 289(3): 104–105.
   PubMedGoogle Scholar
• Castaldi, S., U. Gelatti, U. Hartung, A.M. Moreno-Londono, M. Nobile, and P.J. Schultz. 2012. Use of cognitive enhancement medication among northern Italian university students. Journal of Addiction Medicine, 6(2): 112–117.
   PubMed Web of Science ®Google Scholar
• Chatterjee, A.A. 2006. The promise and predicament of cosmetic neurology. Journal of Medical Ethics 32(2): 110–113.
   PubMed Web of Science ®Google Scholar
• DeGrazia, D. 2000. Prozac, enhancement and self-creation. Hastings Center Report 30(2): 34–40.
   PubMed Web of Science ®Google Scholar
• Elliott, C. 1998. The tyranny of happiness: ethics and cosmetic psychopharmacology. In Enhancing human traits: Ethical and social implications, ed. E. Parens, 177–188. Washington, DC : Georgetown University Press.
   Google Scholar
• Elliott, C. 2008. In defense of the beta blocker. Atlantic Monthly. Available at: http://www.theatlantic.com/magazine/archive/2008/08/in-defense-of-the-beta-blocker/6961 (accessed July 26, 2012).
   Google Scholar
• Farah, M.J. 2012. Neuroethics: The ethical, legal and societal impact of neuroscience. Annual Review of Psychology 63: 571–591.
   PubMed Web of Science ®Google Scholar
• Farah, M.J., J. Illes, R. Cook-Deegan, et al. 2004. Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience 5(5): 421–425.
   PubMed Web of Science ®Google Scholar
• Forlini, C., and E. Racine. 2009. Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: Perspectives of key stakeholders. Neuroethics 2(3): 163–177.
   Web of Science ®Google Scholar
• Forlini, C., and E. Racine. 2012. Added stakeholders, added value(s) to the cognitive enhancement debate: Are academic discourse and professional policies sidestepping values of stakeholders? AJOB Primary Research 3(1): 33–47.
   Google Scholar
• Franke, A.G., C. Bonertz, M. Christmann, S. Engeser, and K. Lieb. 2012. Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: A pilot study. AJOB Primary Research 3(1): 48–57.
   Google Scholar
• Glannon, W. 2011. Brain, body, and mind: Neuroethics with a human face. New York, NY : Oxford University Press.
   Google Scholar
• Goodman, R. 2010. Cognitive enhancement, cheating, and accomplishment. Kennedy Institute of Ethics Journal 20(2): 145–160.
   PubMed Web of Science ®Google Scholar
• Greely, H., B. Sahakian, J. Harris, et al. 2008. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456(7223): 702–705.
   PubMed Web of Science ®Google Scholar
• Hotze, T., K. Shaw, E. Anderson, and M. Wynia. 2011. “Doctor, would you prescribe a pill to help me…?” A national survey of physicians on using medicine for human enhancement. American Journal of Bioethics 11(1): 3–13.
   PubMed Web of Science ®Google Scholar
• Julien, R.M., C.D. Advokat, and J.E. Comaty. 2011. A primer of drug action. New York, NY : Worth.
   Google Scholar
• Kramer, P.D. 1993. Listening to Prozac. London, UK : Fourth Estate.
   Google Scholar
• Lucke, J.C., S. Bell, B. Partridge, and W.D. Hall. 2011. Deflating the neuroenhancement bubble. AJOB Neuroscience 2(4): 38–43.
   Google Scholar
• McCabe, S.E., J.R. Knight, C.J. Teter, and H. Wechsler. 2005. Nonmedical use prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction 100(1): 96–106.
   PubMed Web of Science ®Google Scholar
• Metzinger, T., and E. Hildt. 2011. Cognitive enhancement. In Oxford handbook of neuroethics, ed. J. Illes and B.J. Sahakian, 245–264. Oxford, UK : Oxford University Press.
   Google Scholar
• Outram S.M. 2010. The use of methylphenidate among students: The future of enhancement? Journal of Medical Ethics 36(4): 198–202.
   PubMed Web of Science ®Google Scholar
• Pieters, T., and S. Snelders. 2009. Psychotropic drug use: Between healing and enhancing the mind. Neuroethics 2(2): 1–11.
   Google Scholar
• President's Council on Bioethics. 2003. Beyond therapy. Washington, DC : Harper Collins.
   Google Scholar
• Riis, J, J. Simmons, and G. Goodwin. 2008. Preferences for enhancement pharmaceuticals: The reluctance to enhance fundamental traits. Journal of Consumer Research 35(3): 495–508.
   Web of Science ®Google Scholar
• Sabini, J., and J.R. Monterosso. 2005. Judgments of the fairness of using performance enhancing drugs. Ethics and Behavior 15(1): 81–94.
   PubMed Web of Science ®Google Scholar
• Sattler, S., C. Forlini, E. Racine, and C. Sauer. 2013. Impact of contextual factors and substance characteristics on perspectives toward cognitive enhancement. PLoS One 8(8): e71452. doi:10.1371/journal.pone.0071452
   PubMed Web of Science ®Google Scholar
• Sattler, S., and C. Wiegel. 2013. Test anxiety and cognitive enhancement: The influence of students’ worries on their use of performance-enhancing drugs. Substance Use & Misuse 48(3): 220–232.
   PubMed Web of Science ®Google Scholar
• Schermer, M. 2008. On the argument that enhancement is “cheating.” Journal of Medical Ethics 34: 85–88.
   PubMed Web of Science ®Google Scholar
• Schermer, M., I. Bolt, R. de Jongh, and B. Olivier. 2009. The future of psychopharmacological enhancements: expectations and policies. Neuroethics 2(2): 75–87.
   Web of Science ®Google Scholar
• Smith, M.E., and M.J. Farah. 2011. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin 137(5): 717–741
   PubMed Web of Science ®Google Scholar
• Teter, C.J., S.E. McCabe, K. LaGrange, J.A. Cranford, and C.J. Boyd. 2006. Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy 26(10): 1501–1510.
   PubMed Web of Science ®Google Scholar
• Wilens, T.E., L.A. Adler, J. Adams, et al. 2008. Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry 47(1): 21–31.
   PubMed Web of Science ®Google Scholar